We’re called Molecular Partners for a reason.
Partnership is the core value that defines our company, our research and our product candidates.
Our management team includes many of the scientists who discovered the DARPin® technology at the University of Zurich, and we continue to bring together talented individuals from many disciplines who share our commitment to developing breakthrough medicines for serious diseases.
Our multi-DARPin® proteins also function as a team, combining multiple small proteins with high-specificity, potency and versatility in one therapy. This approach allows us to design medicines that can inhibit multiple disease-specific targets and may improve outcomes for patients living with cancer and sight-threatening diseases and other disorders.
We work with industry leader, Allergan, in the field of ophthalmology to leverage the full potential and reach of our multi-DARPin® platform, creating value for both sides of the partnership.
DARPin® is a registered trademark owned by Molecular Partners AG.